Health Devices. 2011 Aug;40(8):258-62.
After many years of anticipation, FDA has approved a device for breast tomosynthesis applications: The Hologic Selenia Dimensions 3-D. But despite the advantages of the technology, certain issues--such as increased radiation dose, higher costs, and lack of insurance reimbursement--may impede widespread clinical adoption. We take a look at breast tomosynthesis and give our view on its clinical outlook.
经过多年的期待,美国食品药品监督管理局(FDA)已批准一款用于乳腺断层合成应用的设备:Hologic Selenia Dimensions 3-D。然而,尽管该技术具有诸多优势,但某些问题——如辐射剂量增加、成本更高以及缺乏保险报销——可能会阻碍其在临床上的广泛应用。我们来看看乳腺断层合成技术,并对其临床前景发表看法。